Detalhe da pesquisa
1.
Lecanemab in Early Alzheimer's Disease.
N Engl J Med
; 388(1): 9-21, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36449413
2.
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
Ann Neurol
; 95(2): 288-298, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37830926
3.
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Br J Cancer
; 124(1): 237-246, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024271
4.
Concordance of Lumipulse cerebrospinal fluid t-tau/Aß42 ratio with amyloid PET status.
Alzheimers Dement
; 16(1): 144-152, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914216
5.
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Alzheimers Res Ther
; 16(1): 105, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730496
6.
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.
JAMA Netw Open
; 6(4): e237230, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040116
7.
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(1): e12377, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949897
8.
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
Alzheimers Res Ther
; 14(1): 182, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36482412
9.
Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.
Alzheimers Res Ther
; 14(1): 105, 2022 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35897078
10.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
Alzheimers Res Ther
; 14(1): 191, 2022 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36544184
11.
Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.
JAMA Netw Open
; 5(4): e228392, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35446396
12.
Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Clin Cancer Res
; 27(17): 4848-4858, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34108184
13.
Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Alzheimers Dement (N Y)
; 5: 364-373, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31440579